Search clinical trials for: Pulmozyme (dornase alfa)

Total 3100 results

Merck Sharp & Dohme LLC

Terminated

A Study of MK2578 in Patients With Chronic Kidney Disease Who Are Not on Dialysis (2578-002)

Anemia | Chronic Kidney Disease
European Organisation for Research and Treatment...
Charite University, Berlin, Germany; Trans Tasman Radiation Oncology Group; Groupe... and other collaborators

Terminated

Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Head and Neck Cancer

Head and Neck Cancer

France, Belgium, Israel, United Kingdom, Australia, Spain, Germany, Switzerland, Hungary, Netherlands
Northwestern University
National Cancer Institute (NCI)

Completed

Exercise Plus Epoetin Alfa in Treating Cancer Patients Who Have Anemia-Related Fatigue

Fatigue | Anemia | Unspecified Adult Solid Tumor, Protocol Specific

United States
Washington University School of Medicine
National Institute of Neurological Disorders and Stroke (NINDS); PPD; Ortho Biotech...

Withdrawn

Epoetin Alfa for HIV-Associated Neuropathy Trial

HIV Infections | Neuropathy
Biocad

Completed

An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients

Hepatitis | Hepatitis C | Hepatitis C/ Human Immunodeficiency Virus Coinfection

Russian Federation
Xiamen Amoytop Biotech Co., Ltd.
Peking University People's Hospital

Completed

Efficacy and Safety of Ypeginterferon Alfa-2b in Chronic Hepatitis C (PEGIFN)

Chronic Hepatitis C

China
Chiesi Farmaceutici S.p.A.

Not yet recruiting

Analysis of Velmanase Alfa (Lamzede®)'s Effects in the Body of Children With Alpha-Mannosidosis Under the Age 3 (LAMPO(0-3))

Alpha-Mannosidosis
Novo Nordisk A/S

Completed

A Long-term Assessment of Physical Activity, Range of Motion, and Functional Status Following Elective Orthopedic Surgery in Hemophilia Patients With Inhibitors

Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors

United States
David L Rogers, MD

Active, not recruiting

Intravitreal ERT to Prevent Retinal Disease Progression in Children With CLN2

Neuronal Ceroid Lipofuscinosis Type 2

United States
Pfizer

Completed

Nonacog Alfa Prophylaxis And Treatment Of Bleeding Episodes In Previously Treated Patients With Hemophilia B

Hemophilia B

India
Genzyme, a Sanofi Company

Completed

Evaluate Efficacy and Safety in Chinese Patients With Infantile-Onset Pompe Disease With One Year Alglucosidase Alfa Treatment (APOLLO-IOPD)

Glycogen Storage Disease Type II

China
Genzyme, a Sanofi Company

Completed

Pharmacokinetics of Alglucosidase Alfa in Patients With Pompe Disease (PAPAYA)

Pompe Disease | Glycogen Storage Disease Type II (GSD II)

United States, Russian Federation, United Kingdom, Bulgaria, India, Ukraine
Shire

Completed

This Study is Designed to Evaluate PD/PK and Safety of Replagal Manufactured by Two Different Processes.

Fabry Disease

Canada
Shire
Quintiles, Inc.

Completed

Multicenter Extension Study of Velaglucerase Alfa in Japanese Patients With Gaucher Disease

Gaucher Disease

Japan
Chiesi Farmaceutici S.p.A.

Withdrawn

Interventional Study to Assess Efficacy and Safety of Velmanase Alfa in Patients With Alpha Mannosidosis (SHAMAN)

Alpha-Mannosidosis
Alexion Pharmaceuticals

Completed

Pharmacokinetic and Dose Response Study of Asfotase Alfa in Adult Patients With Pediatric-Onset Hypophosphatasia (HPP)

Hypophosphatasia

United States, Germany
Genzyme, a Sanofi Company

Completed

rhGAA in Patients With Infantile-onset Glycogen Storage Disease-II (Pompe Disease)

Glycogen Storage Disease Type II | Acid Maltase Deficiency Disease | Glycogenosis 2 | Pompe Disease

United States, Israel, France, United Kingdom
Genzyme, a Sanofi Company

Completed

A Study of the Safety and Efficacy of rhGAA in Patients With Infantile-onset Pompe Disease

Glycogen Storage Disease Type II

United States, Taiwan, Israel, United Kingdom, France
Groupe Francophone des Myelodysplasies

Recruiting

A Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS (EPO-PRETAR)

Myelodysplastic Syndromes

France
Biocad

Completed

The Study of PK, PD, Safety of Multiple Intravenous Injections of BCD-066 and Aranesp in Healthy Volunteers

Healthy

Russian Federation
Astellas Pharma Inc

Completed

A Study to Investigate the Effect of ASP1517 After Intermittent Oral Dosing in Dialysis Chronic Kidney Disease Patients With Anemia Compared With Darbepoetin as a Reference Drug

Renal Anemia Associated With Chronic Renal Failure (CRF)

Japan
M.D. Anderson Cancer Center
Ortho Pharmaceuticals

Terminated

A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Weekly Procrit Given to Gastric or Rectal Patients

Rectal Cancer | Gastrointestinal Cancer

United States
Hoffmann-La Roche

Completed

COMFORT Study: A Crossover Study of NeoRecormon (Epoetin Beta) and Darbepoetin Alfa in Patients With Renal Anemia.

Anemia

Australia
Amgen

Completed

An Evaluation of Aranesp® in Subjects With Anaemic Chronic Kidney Disease (CKD)

Kidney Disease
Ortho Pharmaceuticals

Completed

The Safety and Effectiveness of r-HuEPO in Patients With AIDS or Advanced AIDS-Related Complex (ARC) Who Are Anemic

HIV Infections | Cytopenias

United States
Ortho Pharmaceuticals

Completed

A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy

HIV Infections | Cytopenias

United States
Ortho Pharmaceuticals

Completed

A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS and Advanced ARC Patients With Anemia

HIV Infections | Cytopenias

United States
AM-Pharma
FGK Clinical Research GmbH

Recruiting

Ilofotase Alfa for Prevention of Renal Damage After Cardiac Surgery

Open Heart Surgery

Germany
Alexion Pharmaceuticals, Inc.

Recruiting

Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa (CHESTNUT)

Hypophosphatasia

Australia, United States, Japan, Germany, Turkey, Italy, India, France, United Kingdom, Argentina, Canada
Alexion

Recruiting

A Prospective Sub-Study of the Global Hypophosphatasia Registry

Hypophosphatasia

United States
The University of Hong Kong

Recruiting

Ropeginterferon Alfa 2b for Early Myelofibrosis

Myelofibrosis | Primary Myelofibrosis, Prefibrotic Stage

Hong Kong
Sanofi

Recruiting

Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa (Baby-COMET)

Glycogen Storage Disease Type II

Belgium, United States, China, Germany, Italy, Netherlands, Spain, Taiwan, United Kingdom
Takeda

Active, not recruiting

A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher Disease

Gaucher Disease

China
Amgen

Completed

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efavaleukin Alfa in Participants With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

United States, Poland, Germany, France
UNICANCER
Merck KGaA, Darmstadt, Germany

Terminated

Evaluation of Bintrafusp Alfa in Operable and Untreated Head and Neck Squamous Cell Carcinoma (ICING)

Squamous Cell Carcinoma of Head and Neck

France
Organon and Co

Completed

A Post Marketing Observational Study of the Safety and Efficacy of Elonva (Corifollitropin Alfa) in General Practice (P08165)

Infertility, Female
Shire

Completed

A Multicenter Open-Label Treatment Protocol to Observe the Safety of Replagal (Agalsidase Alfa) Enzyme Replacement Therapy in Canadian Patients With Fabry Disease

Fabry Disease

Canada
Shire

No longer available

Treatment Protocol of Replagal for Patients With Fabry Disease

Fabry Disease

United States
Shaare Zedek Medical Center

Completed

Rapid Intravenous Infusion of Velaglucerase Alfa (VPRIV) in Treatment-naive Patients With Type 1 Gaucher Disease

Primary Disease

Israel
LMU Klinikum
Genzyme, a Sanofi Company

Completed

Long-term Outcome in Late-onset Pompe Disease Treated Beyond 36 Months (STIG-Pompe-Study) (STIG)

Pompe Disease

Germany, Taiwan, Italy
Baylor Research Institute
Texas Scottish Rite Hospital for Children

Withdrawn

The Effect of Velaglucerase Alfa (Vpriv) on Skeletal Development in Pediatric Gaucher Disease

Gaucher Disease Type 1 | Gaucher Disease Type 3

United States
Pfizer

Completed

Study To Compare On-Demand Treatment To A Prophylaxis Regimen Of BeneFIX In Subjects With Moderately Severe to Severe Hemophilia B

Hemophilia B

Canada, Singapore, Turkey, Croatia, Korea, Republic of, Mexico, Poland, Bulgaria, Malaysia
Shin Kong Wu Ho-Su Memorial Hospital

Unknown

Corifollitropin Alfa Application in PCOS Patients

In Vitro Fertilization

Taiwan
Genzyme, a Sanofi Company

Completed

Extension Study of Patients With Infantile-Onset Pompe Disease Who Were Previously Enrolled in Protocol AGLU01602

Glycogen Storage Disease Type II

United States, France, Germany, Israel, Italy, Netherlands, Taiwan
Genzyme, a Sanofi Company

Completed

A Study of rhGAA in Patients With Late-Onset Pompe Disease

Pompe Disease (Late-onset) | Glycogen Storage Disease Type II (GSD-II) | Acid Maltase Deficiency Disease | Glycogenosis 2

Netherlands
Genzyme, a Sanofi Company

Completed

Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Late-onset Pompe Disease

Glycogen Storage Disease Type II | Glycogenosis 2

United States
Genzyme, a Sanofi Company

Completed

Extension Study of Long-term Safety and Efficacy of Myozyme for a Single Patient With Pompe Disease Who Were Previously Enrolled in Genzyme Sponsored ERT Studies.

Pompe Disease Late-Onset | Glycogen Storage Disease Type II GSD II

United States
Genzyme, a Sanofi Company

Completed

Safety and Effectiveness Study of rhGAA in Patients With Advanced Late-Onset Pompe Disease Receiving Respiratory Support

Pompe Disease (Late-onset) | Glycogen Storage Disease Type II (GSD-II) | Acid Maltase Deficiency Disease | Glycogenosis 2

France
H. Lee Moffitt Cancer Center and Research Institute
Novartis Pharmaceuticals

Recruiting

Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA

Myelodysplastic Syndromes

United States
UMC Utrecht
The Hospital for Sick Children; Alberta Children's Hospital

Recruiting

Darbepoetin for Ischemic Neonatal Stroke to Augment Regeneration (DINOSAUR)

Perinatal Stroke | Neonatal Stroke | PAIS

Netherlands

3

Subscribe